Difluprednate Ophthalmic · Regulatory label update

FDA supplemental approval: Difluprednate Ophthalmic (Labeling)

U.S. Food and Drug Administration · August 12, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is a regulatory approval record documenting a supplemental labeling change for difluprednate ophthalmic (Durezol 0.05% emulsion) by Sandoz, approved by the FDA on 12 August 2026. The record does not contain clinical trial results, efficacy data, or comparative evidence, and therefore cannot be used to assess clinical benefit or practice implications.

What was studied

Regulatory label update.

Key findings

Safety

This is a regulatory action record only; no clinical trial data, efficacy outcomes, or safety data are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for labeling change to difluprednate ophthalmic; does not report clinical trial outcomes or comparative efficacy data.

Caveats

This is a regulatory action record only; no clinical trial data, efficacy outcomes, or safety data are reported.
The specific nature of the labeling change is not detailed in this record.
No information on comparator products, indication, or population affected is provided.
Readers requiring clinical evidence should consult the full product labeling or FDA summary of basis for approval.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no study design applicable.

Directness

insufficient

Labeling supplement; no clinical outcome data reported.

Consistency

insufficient

Single regulatory action; consistency not assessable.

Risk of bias

insufficient

Not a clinical trial; bias assessment not applicable.

Sample adequacy

insufficient

No sample size or population studied in this record.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application NDA022212. This is a regulatory action record, not a clinical study. Brand name: DIFLUPREDNATE OPHTHALMIC. Active ingredient: DIFLUPREDNATE OPHTHALMIC. Sponsor: SANDOZ. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-08-12. Products: DUREZOL, EMULSION, OPHTHALMIC, DIFLUPREDNATE 0.05%.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

SandozDifluprednate Ophthalmic